BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bejder J, Robach P, Lundby A, Cornu C, Sallet P, Cairo G, Lundby C. Low doses of recombinant human erythropoietin does not affect C‐terminal FGF23 in healthy men. Drug Test Anal 2020;12:975-9. [DOI: 10.1002/dta.2795] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Thevis M, Kuuranne T, Geyer H. Annual banned-substance review: Analytical approaches in human sports drug testing 2019/2020. Drug Test Anal 2021;13:8-35. [PMID: 33185038 DOI: 10.1002/dta.2969] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
2 Reichel C, Erceg D, Lorenc B, Scheiblhofer V, Farmer L, Zanitzer K, Geisendorfer T, Gmeiner G, Thevis M. Data from a microdosed recombinant human erythropoietin administration study applying the new biotinylated clone AE7A5 antibody and a further optimized sarcosyl polyacrylamide gel electrophoresis protocol. Drug Test Anal 2021. [PMID: 33450134 DOI: 10.1002/dta.2989] [Cited by in F6Publishing: 1] [Reference Citation Analysis]